Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDNA 55

Drug Profile

MDNA 55

Alternative Names: cpIL4-PE; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4(38-37)-PE38KDEL; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321

Latest Information Update: 11 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); Neurocrine Biosciences
  • Developer Medicenna Therapeutics; Sophiris Bio
  • Class Antineoplastics; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Brain metastases
  • Preclinical Brain cancer; Glioma
  • Research Bladder cancer
  • Discontinued Solid tumours

Most Recent Events

  • 14 Feb 2019 Medicenna plans a phase II trial for Glioblastoma (First line-therapy)in the second half of 2019
  • 08 Feb 2019 Interim efficacy data from a phase II trial in recurrent Glioblastoma released by Medicenna Therapeutics
  • 31 Oct 2018 Medicenna plans an end-of-phase II meeting with US FDA in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top